Tacrolimus ointment improves psoriasis in a microplaque assay

British Journal of Dermatology

Volumn 141, Issue 1, 1999, Pages 103-107

  Remitz, A ^a   Reitamo, S ^a   Erkko, P ^a   Granlund, H ^a   Lauerma, A I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic plaque psoriasis; Ointment formulation; Tacrolimus (FK506)

Indexed keywords

ADIPIC ACID DIISOPROPYL ESTER; BETAMETHASONE VALERATE; CALCIPOTRIOL; DRUG VEHICLE; PENETRATION ENHANCING AGENT; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ERYTHEMA; FEMALE; HUMAN; MALE; OINTMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNIVERSITY HOSPITAL;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; SKIN TESTS; STATISTICS, NONPARAMETRIC; TACROLIMUS;

EID: 0032863339     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02927.x     Document Type: Article

References (15)

1. Spencer CM, Goa KL, Gillis JC. Tacrolimus: An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75.
2. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): A multicentre study. Br J Dermatol 1997; 136: 527-30.
3. Abu-Elmagd K, van Thiel D, Jegasothy BV et al. FK 506: A new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991; 23: 3322-4.
4. Jegasothy BV, Ackerman CD, Todo S et al. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-5.
5. Lemster B, Rilo HR, Carroll PB et al. FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. Am J NY Acad Sci 1993; 696: 250-6.
6. European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol J 1996; 132: 419-23.
7. Thomson AW, Nalesnik M, Abu-Elmagd K, Starzl TE. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: A preliminary study. Transplant Proc 1991; 23: 3330-1.
8. Boguniewicz M, Leung DYM. Management of atopic dermatitis. In: Atopic Dermatitis: From Pathogenesis to Treatment (Leung DYM, ed.). Austin: RG Landes Company of Chapman & Hall, 1996; 185-220.
9. Rappersberger K, Meingassner JG, Fialla R et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106: 701-10.
10. Sprent P. Applied Nonparametric Statistical Methods. London: Chapman & Hall, 1989.
11. Goto T, Kino T, Hatanaka H, et al. FK 506: Historical perspectives. Transplant Proc 1991; 23: 2713-17.
12. Ruzicka T, Reitamo S, Bieber T. Tacrolimus ointment for atopic dermatitis. N Engl J Med 1998; 339: 1788-9.
13. Murdoch D, Clissold SP. Calcipotriol: A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992; 43: 415-29.
14. Zonneveld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol 1998; 134: 1101-2.
15. Ruzicka T, Bieber T, Schoepf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21.